RUNX2 and neoplasm: miRNAs have emerged as key players in cancer progression and metastatic initiation yet the importance of miRNAs in regulating prostate cancer bone metastasis has just begun to be appreciated.36 In this study, we have identified miR-466 as a suppressor of prostate cancer growth and metastasis through direct targeting of the bone-related transcription factor RUNX2, which is difficult to target by conventional pharmacologic approaches.33, 37 Our in vivo xenograft studies provide evidence that miR-466 can inhibit primary orthotopic tumor growth and spontaneous metastasis to bone.